Evidence map›Paper›PMID 41397763›Full record

ArticleBMJ open2025

Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD).

Wei Zhang, Yalan Dou, Jiaojiao Liu, Tianyi Liu, Weili Yan, Qian Shen, Hong Xu, Yihui Zhai

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06890143 (The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06890143 phase3recruitingnot on this map

The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

TypeinterventionalSponsorChildren's Hospital of Fudan UniversityRan2025 to 2027Enrolled44ConditionsPediatric Hereditary Kidney DiseasesArmsDapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei Zhang *Department of Nephrology, Children's Hospital of Fudan University, Shanghai, China.
Yalan Dou *Clinical Trial Unit, Children's Hospital of Fudan University, Shanghai, China.
Jiaojiao LiuDepartment of Nephrology, Children's Hospital of Fudan University, Shanghai, China.
Tianyi LiuDepartment of Nephrology, Children's Hospital of Fudan University, Shanghai, China.
Weili YanClinical Trial Unit, Children's Hospital of Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-7633-7449
Qian ShenDepartment of Nephrology, Children's Hospital of Fudan University, Shanghai, China.
Hong XuDepartment of Nephrology, Children's Hospital of Fudan University, Shanghai, China yhzhai@fudan.edu.cn hxu@shmu.edu.cn.ORCID http://orcid.org/0000-0001-7617-0872
Yihui ZhaiDepartment of Nephrology, Children's Hospital of Fudan University, Shanghai, China yhzhai@fudan.edu.cn hxu@shmu.edu.cn.ORCID http://orcid.org/0000-0001-7593-5538

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSodium-glucose cotransporter-2 inhibitors have demonstrated cardiorenal protective effects in adults with chronic kidney disease (CKD), but their efficacy and safety in paediatric CKD remain uncertain. Treatment for hereditary kidney disease in children is limited. This DAPA-PedHKD study aims to evaluate the effectiveness and safety of combining renin-angiotensin-aldosterone system inhibitors (RAASi) with dapagliflozin compare to RAASi alone in children with hereditary kidney disease accompanied by proteinuria. METHODS AND ANALYSIS: DAPA-PedHKD is a multicentre, randomised, crossover, open-label clinical trial. Patients aged 6-18 years with hereditary kidney disease will be eligible. All patients must have received stable RAASi therapy for at least 4 weeks, with a baseline estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of the Children's Hospital of Fudan University and 11 local ethics committees. We will publish results in peer-reviewed journals and present at international conferences. TRIAL REGISTRATION NUMBER: NCT06890143.

Indexed as

Angiotensin-Converting Enzyme InhibitorsBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsAdolescentChildCross-Over StudiesDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansMaleMulticenter Studies as TopicProspective StudiesProteinuriaRandomized Controlled Trials as TopicAngiotensin-Converting Enzyme InhibitorsBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsChildClinical trialsPaediatric nephrology

Identifiers

PMID41397763
PMCPMC12706236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.